Human reproduction openPub Date : 2026-10-23eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag095
Michael Zitzmann, Stefan Schlatt, Ebo Nieschlag, Ndema Habib, Mario Festin, David J Handelsman, Robert McLachlan, Maria Cristina Meriggiola, Gabriela Noé, Silvia Lestari, Hermann M Behre, Frederick Wu, Richard A Anderson
{"title":"Integrating hormonal analyses into the development of hormonal male contraception: geographic centre as a determinant of individual response.","authors":"Michael Zitzmann, Stefan Schlatt, Ebo Nieschlag, Ndema Habib, Mario Festin, David J Handelsman, Robert McLachlan, Maria Cristina Meriggiola, Gabriela Noé, Silvia Lestari, Hermann M Behre, Frederick Wu, Richard A Anderson","doi":"10.1093/hropen/hoag095","DOIUrl":"https://doi.org/10.1093/hropen/hoag095","url":null,"abstract":"<p><strong>Study question: </strong>Are the geographic recruitment centre and dynamic sex-steroid profiles, particularly for dihydrotestosterone, associated with inter-individual differences in libido and mood-related adverse events during hormonal male contraception?</p><p><strong>Summary answer: </strong>In this multinational analysis of the WHO testosterone undecanoate/norethisterone (TU/NETE) enanthate trial, geographic cluster was associated with distinct androgenic profiles and clinical responses; lower dihydrotestosterone exposure emerged as a consistent predictor of decreased libido and mood-related adverse events.</p><p><strong>What is known already: </strong>Combined testosterone-progestin regimens can suppress spermatogenesis effectively, but the WHO TU/NETE trial was discontinued prematurely because of mood-related adverse events despite high contraceptive efficacy. The endocrine mechanisms underlying these adverse effects remain incompletely understood.</p><p><strong>Study design size duration: </strong>This secondary analysis used serial hormone and adverse-event data from the multinational WHO/CONRAD trial, which enrolled 320 men. However, 255 participants had serum samples available for centralized steroid analysis and constituted the present analytical cohort, as the samples from Jakarta, Indonesia (65 subjects) were not sent to the Central Laboratory.</p><p><strong>Participants/materials setting methods: </strong>Healthy male participants were recruited across European/Australian, South American, and Asian centres and grouped into geographic clusters. Serum testosterone, calculated free testosterone, dihydrotestosterone, estradiol, and norethisterone were analysed centrally by gas chromatography-mass spectrometry (GC-MS). Longitudinal mixed-effects models and time-to-event analyses were used to evaluate associations between hormone trajectories, geographic cluster, age, libido changes, and mood disorders.</p><p><strong>Main results and the role of chance: </strong>Marked cluster-dependent heterogeneity was observed. Participants from Chile showed higher total and free testosterone and persistently higher dihydrotestosterone concentrations over time, accompanied by a higher incidence of increased libido. Participants from India showed lower dihydrotestosterone exposure and higher norethisterone concentrations and no libido and mood changes. European/Australian participants showed comparatively lower dihydrotestosterone concentrations and the highest cumulative incidence of mood disorders. Declining dihydrotestosterone concentrations were associated with decreased libido and mood-related adverse events.</p><p><strong>Limitations reasons for caution: </strong>The analyses are exploratory and based on secondary evaluation of a completed clinical trial. Geographic clusters may reflect genetic, environmental, dietary, cultural, behavioural, and reporting-related factors, and causality cannot be inferred.</p><p><strong>Wider implicatio","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag095"},"PeriodicalIF":8.6,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13755873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-10-19eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag091
{"title":"Correction to: Menstrual fluid-derived small extracellular vesicles: a novel reservoir with distinct molecular signatures and implications for endometriosis etiopathology.","authors":"","doi":"10.1093/hropen/hoag091","DOIUrl":"https://doi.org/10.1093/hropen/hoag091","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/hropen/hoag020.].</p>","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag091"},"PeriodicalIF":8.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149229475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-10-19eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag096
Hafsa Gulzar, Richard Musson, Joanna Depciuch, Łukasz Gąsior, Simona Bisogno, Michał Sarna, Maria Florencia Heber, Julia Skałka, Diego Alejandro Molina, Michał Kiełbus, Anna Bodzon-Kulakowska, Piotr Suder, Lulu Alluhaibi, Alexey Maximenko, Grażyna E Ptak
{"title":"Oocyte lipid damage from maternal ageing marks neurodevelopment in mouse offspring.","authors":"Hafsa Gulzar, Richard Musson, Joanna Depciuch, Łukasz Gąsior, Simona Bisogno, Michał Sarna, Maria Florencia Heber, Julia Skałka, Diego Alejandro Molina, Michał Kiełbus, Anna Bodzon-Kulakowska, Piotr Suder, Lulu Alluhaibi, Alexey Maximenko, Grażyna E Ptak","doi":"10.1093/hropen/hoag096","DOIUrl":"https://doi.org/10.1093/hropen/hoag096","url":null,"abstract":"<p><strong>Study question: </strong>Is advanced maternal age (AMA) associated with lipid dysregulation in oocytes that correlates with the intergenerational persistence of altered lipid homeostasis and neurodevelopmental pathway signatures in downstream offspring?</p><p><strong>Summary answer: </strong>Lipid profile alterations characterized in AMA oocytes are associated with distinct lipidomic and spectral variations in the foetal brain and yolk sac, displaying intergenerational persistence that extends up to the fourth generation (F4), independently of the gestational uterine environment.</p><p><strong>What is known already: </strong>AMA is a recognized prenatal risk factor for neurodevelopmental conditions in offspring. However, whether early-life oocyte lipid variations correlate with altered lipid profiles and molecular signatures in the developing brains of subsequent generations remain uncharacterized.</p><p><strong>Study design size duration: </strong>This controlled animal model study compared oocytes, blastocysts, and foetuses from AMA mice (8-16 months old) to those from young maternal age (YMA, 3-4 months old) controls and featured an embryo transfer (ET) of AMA blastocysts into young surrogates and longitudinal, lineage-specific tracking up to the F4.</p><p><strong>Participants/materials setting methods: </strong>Complementary approaches, including liquid chromatography-mass spectrometry (LC-MS) proteomics and lipidomics, Matrix-Assisted Laser Desorption/Ionization-Tandem Time-of-Flight mass spectrometry (MALDI-TOF/TOF MS), RNA sequencing, atomic force microscopy, Coherent Anti-Stokes Raman Scattering (CARS) chemical imaging microscopy, Raman and Fourier transform infrared (FTIR) spectroscopies, and histology were conducted on single oocytes, blastocysts, and foetal structures (brain and yolk sac) from AMA and YMA mice. ET was utilized to decouple the oocyte-derived phenotype from the effects of an ageing maternal uterine environment.</p><p><strong>Main results and the role of chance: </strong>AMA oocytes and preimplantation blastocysts exhibited significant lipid droplet and lipid membrane alterations, a higher relative absorbance of intracellular lipid bands, and altered expression of lipid-regulatory transcripts, corresponding to early embryonic pathway shifts. Following the ET of AMA blastocysts to young surrogates (ET AMA group), distinct lipidomic variations and structural alterations were observed in the F1 yolk sac and foetal brains. Furthermore, these lipid-associated spectral and molecular signatures displayed intergenerational persistence, tracking through the yolk sac, brain, and oocytes of the third- (F3) and fourth-generation (F4) descendants derived from the oocyte of AMA progenitors.</p><p><strong>Large scale data: </strong>The transcriptomic data have been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE349634. Processed transcriptomic, lipidomic, and proteomic datasets, together with th","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag096"},"PeriodicalIF":8.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13760212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-10-14eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag090
Daniela P A F Braga, Amanda S Setti, Maite Del Collado, Jullin Fjeldstad, Parisa Mojiri, Melissa Cavagnoli, Edson Borges
{"title":"Are women cryopreserving enough oocytes for fertility preservation? A probabilistic model integrating AI-based oocyte morphology and age-dependent euploidy.","authors":"Daniela P A F Braga, Amanda S Setti, Maite Del Collado, Jullin Fjeldstad, Parisa Mojiri, Melissa Cavagnoli, Edson Borges","doi":"10.1093/hropen/hoag090","DOIUrl":"https://doi.org/10.1093/hropen/hoag090","url":null,"abstract":"<p><strong>Study question: </strong>How many mature oocytes are biologically required to achieve at least three euploid blastocysts, by maternal age and AI-derived oocyte quality, and how does this estimate compare with real-world oocyte yields in elective fertility preservation?</p><p><strong>Summary answer: </strong>Required oocyte numbers rise steeply with advancing maternal age and decreasing AI-derived oocyte quality, and the median number cryopreserved per fertility preservation cycle falls progressively below estimated requirements, by 12- to 30-fold in women older than 40 years.</p><p><strong>What is known already: </strong>Elective oocyte cryopreservation is increasingly used to preserve future reproductive potential, but counselling typically relies on uniform age-based oocyte targets that do not account for inter-individual variability in oocyte biological competence. Although AI-based oocyte assessment has shown promise as an objective adjunct to morphological evaluation, no biologically integrated framework has been used to translate AI-derived oocyte quality into a quantitative requirement-versus-yield comparison in fertility preservation.</p><p><strong>Study design size duration: </strong>Retrospective cohort study with probabilistic modelling of blastulation and euploidy, using three datasets from a single private university-affiliated IVF centre. Model development used 13 782 mature oocytes from 1625 autologous ICSI cycles (1020 patients, 2021-2024) and 3325 biopsied embryos with conclusive PGT-A results (857 patients). External validation was performed in 1948 oocytes from 333 ovum donation cycles in 271 donors (2020-2024). Real-world application used 1647 elective fertility preservation cycles in 1100 patients between 2012 and 2024.</p><p><strong>Participants/materials setting methods: </strong>Each oocyte was scored using a commercially available artificial-intelligence image-analysis system that assigns a 0-10 oocyte quality score. Blastulation and euploidy were modelled by logistic regression with cluster-robust standard errors. The integrated probabilistic framework computed the minimum number of mature oocytes required to obtain at least three euploid blastocysts at a probability of 90% or greater, by maternal age category and tertile of AI-derived oocyte quality score. Model-derived requirements were compared with the median number of oocytes actually cryopreserved per fertility preservation cycle.</p><p><strong>Main results and the role of chance: </strong>Blastulation increased with higher AI-derived oocyte quality score (OR 1.19 per point, 95% CI 1.18-1.21; <i>P</i> < 0.001) and decreased with maternal age (OR 0.94 per year, 95% CI 0.93-0.96; <i>P</i> < 0.001); the oocyte quality effect was externally validated in donors (OR 1.11 per point, 95% CI 1.08-1.14). Euploidy declined non-linearly with age, from 68.6% (<30 years) to 19.3% (>40 years). Estimated mature-oocyte requirements ranged from 9 (95% CI 8-11) at <30 year","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag090"},"PeriodicalIF":8.6,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply: The value of sperm DNA fragmentation testing in clinical practice: routine or case-directed?","authors":"Srisailesh Vitthala, Tarek El-Toukhy, Abha Maheshwari","doi":"10.1093/hropen/hoag088","DOIUrl":"10.1093/hropen/hoag088","url":null,"abstract":"","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag088"},"PeriodicalIF":8.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-10-09eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag087
Ahmad Majzoub, Peter Humaidan
{"title":"The value of sperm DNA fragmentation testing in clinical practice: routine or case-directed?","authors":"Ahmad Majzoub, Peter Humaidan","doi":"10.1093/hropen/hoag087","DOIUrl":"https://doi.org/10.1093/hropen/hoag087","url":null,"abstract":"","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag087"},"PeriodicalIF":8.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-10-06eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag089
Gylli Mola, Margit Bistrup Fischer, Hanne Frederiksen, Jørgen Holm Petersen, Lone Scheel, Katrine Bak Wraae, Ane Lilleøre Rom, Hanne Kristine Hegaard, David Møbjerg Kristensen, Anders Juul, Casper P Hagen
{"title":"Prenatal exposure to paracetamol is associated with smaller testicular volume: a COPANA cohort study of 287 healthy infant boys.","authors":"Gylli Mola, Margit Bistrup Fischer, Hanne Frederiksen, Jørgen Holm Petersen, Lone Scheel, Katrine Bak Wraae, Ane Lilleøre Rom, Hanne Kristine Hegaard, David Møbjerg Kristensen, Anders Juul, Casper P Hagen","doi":"10.1093/hropen/hoag089","DOIUrl":"https://doi.org/10.1093/hropen/hoag089","url":null,"abstract":"<p><strong>Study question: </strong>Is prenatal exposure to paracetamol associated with testicular function in male offspring?</p><p><strong>Summary answer: </strong>Prenatal paracetamol exposure was associated with smaller testicular volume in infant boys.</p><p><strong>What is known already: </strong>Paracetamol (also known as acetaminophen) is available over the counter and is frequently used by pregnant women. Animal studies and secondary analyses of mother-child cohorts suggest paracetamol can adversely affect testicular development. To our knowledge, this is the first cohort study primarily designed to test the association between prenatal paracetamol exposure and postnatal testicular function.</p><p><strong>Study design size duration: </strong>Prospective, observational pregnancy and birth cohort at a university hospital (2020-2022). Healthy, singleton pregnant women (n = 685) were enrolled during the first trimester, and 589 (287 boys) infants completed follow-up examination at 3 months of age.</p><p><strong>Participants/materials setting methods: </strong>Data on maternal paracetamol use (yes/no and dose) were collected prospectively every 2 weeks throughout pregnancy. Based on the timing of fetal masculinization, participants were classified as exposed at any time during fetal life (n = 137), early exposure (gestational week (GW) <b>≤</b> 15; n = 81), late exposure (GW <b>></b>15; n = 118), or exposed during both early and late fetal life (n = 62). Unexposed boys served as controls (n = 150).The boys were examined at infancy (i.e. minipuberty at mean age 3.1 months ±0.3 SD). Predefined primary outcomes: anogenital distance (AGD), testicular volume, and circulating levels of testosterone.</p><p><strong>Main results and the role of chance: </strong>Across exposure windows, prenatal paracetamol exposure was consistently associated with smaller testicular volume at 3 months of age. Effect estimates were largest in boys exposed at early as well as late fetal life; dose of paracetamol, median (interquartile range (IQR)) 8.5 g (4.0-16.6), testicular volume (β) -34.1 mm³, 95% CI -65.5 to -2.7, <i>P</i> = 0.033.</p><p><strong>Limitations reasons for caution: </strong>Residual confounding by indication cannot be excluded. The generalizability of the study may be affected by the homogeneity of the Copenhagen Analgesic Study (COPANA) cohort. Longitudinal follow-up is necessary for evaluation of reproductive health in adulthood.</p><p><strong>Wider implications of the findings: </strong>In this prospective human cohort study, prenatal paracetamol exposure was associated with reduced testicular volume during minipuberty, a transient period of postnatal activation of the hypothalamic-pituitary-gonadal axis that is considered a critical window for assessing future reproductive function.</p><p><strong>Funding: </strong>Rigshospitalet Research Council supports this work under grants (E-22778-02) and (E-22717-21). The research was furthermore funded by Læ","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag089"},"PeriodicalIF":8.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13716481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149302062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-09-30eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag086
Li Du, Yinuo Zhang
{"title":"AI-assisted IVF company websites: a content analysis of marketing claims, information quality, legal and ethical issues.","authors":"Li Du, Yinuo Zhang","doi":"10.1093/hropen/hoag086","DOIUrl":"https://doi.org/10.1093/hropen/hoag086","url":null,"abstract":"<p><strong>Study question: </strong>How do providers of AI-assisted IVF products and services present their AI systems, characterize their products and services, and address patient privacy and data protection concerns on their websites?</p><p><strong>Summary answer: </strong>Websites of AI-assisted IVF providers predominantly emphasize benefits while failing to disclose risks, provide insufficient information about AI systems and data sources, and inadequately address privacy protection, with none of them including AI-specific provisions in their privacy policies.</p><p><strong>What is known already: </strong>Websites promoting AI-assisted products and services for IVF treatments are a key information source for patients, can shape perceptions about this advanced technology, and have an impact on patients' treatment decisions. However, the way providers present such services on their websites has not been previously studied.</p><p><strong>Study design size duration: </strong>Using online searches and a review of research abstracts presented at the 2022 ESHRE annual meeting, we identified 21 companies offering AI-assisted IVF products or services. Website content was captured between 15 and 22 August 2023, and content analysis was done between 25 August and 15 September 2023. In response to an external reviewer's recommendation, we did a follow-up review on 30 June 2026.</p><p><strong>Participants/materials setting methods: </strong>Twenty-one companies (7 IVF equipment producers, 14 exclusively developing AI-assisted IVF products) based in Europe (n = 9), Israel (n = 4), Canada/USA (n = 5), and China (n = 3) were evaluated in this study. The companies collectively offered 30 AI tools including embryo quality assessment, oocyte quality assessment, sperm analysis, endometrial receptivity analysis, and ovarian stimulation optimization. A subset of 10 companies' websites was used for thematic content analysis and the resulting themes were used to develop a coding book with 22 questions examining (i) benefit and risk descriptions; (ii) AI system explanations and performance; (iii) data protection and privacy issues; and (iv) portrayal of products/services. The coding book was finalized and subsequently applied by one of the authors to complete an analysis of the entire dataset. Based on an external reviewer's suggestion, we also analyzed the AI models on providers' websites. Independent coding of 60% of samples achieved almost perfect inter-coder agreement (Cohen's Kappa: 0.831-1.000).</p><p><strong>Main results and the role of chance: </strong>All 21 websites (100%) mentioned benefits of AI-assisted IVF, with the most frequently cited benefit being 'increased accuracy' (specific to each provider's product or service) (61.9%, n = 13). However, no websites explicitly outlined potential risks associated with AI use. Twenty companies (95.2%) described their AI systems, yet only 33.3% (n = 7) disclosed sample sizes used for AI development, and only 23.8%","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag086"},"PeriodicalIF":8.6,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13690092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-09-23eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag085
TingTing Shao, Achilleas Ghinis, Eline Dancet, Johanna Devroe, Felipe Kenji Nakano, Celine Vens
{"title":"Discrete time survival analysis machine learning models for IVF prognosis across multiple cycles.","authors":"TingTing Shao, Achilleas Ghinis, Eline Dancet, Johanna Devroe, Felipe Kenji Nakano, Celine Vens","doi":"10.1093/hropen/hoag085","DOIUrl":"https://doi.org/10.1093/hropen/hoag085","url":null,"abstract":"<p><strong>Study question: </strong>Can discrete time survival analysis machine learning (ML) methods provide reliable and accurate predictions of cumulative live birth rate (CLBR) for patients both at diagnosis (pre-treatment) and after the first cycle of treatment (post-treatment)?</p><p><strong>Summary answer: </strong>We developed discrete time survival analysis ML models that provide personalized CLBR estimates of up to six complete IVF cycles with good discriminative performance, especially at the post-treatment phase.</p><p><strong>What is known already: </strong>The first relevant prognostic models to estimate IVF cumulative success rate across multiple cycles have moderate performance, with C-statistics ranging from 0.7 to 0.73 for both pre-treatment and post-treatment models.</p><p><strong>Study design size duration: </strong>This retrospective, single-center study included a cohort of 1429 couples who started their IVF treatment at a tertiary center between January 2014 and April 2021 as the development dataset. An additional 613 couples who started treatment at the same center between April 2021 and December 2023 were used as the temporal validation dataset.</p><p><strong>Participants/materials setting methods: </strong>Predictive performance was assessed using the following metrics: prediction error (Brier score, scaled Brier score), time-dependent AUC (cumulative/dynamic AUC, mean AUC, and time-dependent precision-recall AUC), and calibration (mean calibration, calibration plot, and calibration slope). Both pre-treatment and post-treatment models predicted the cumulative live birth success rates of up to six complete IVF cycles. Various discrete time survival analysis methods were trained, evaluated, and compared with the baseline models. Discrete time survival analysis models include the ones embedded with a generalized linear model (Logit) and tree-based ensembles (Bayesian Additive Regression Trees (BART), random forests). The baseline models are the refitted/recalibrated pre-treatment and post-treatment McLernon models, considering factors available in our data.</p><p><strong>Main results and the role of chance: </strong>The discrete time survival analysis models, especially BART, performed better on our data than the baseline models especially at the post-treatment phase. Validation results showed moderate discriminative ability for the pre-treatment model, with a mean AUC 0.69 (95% CI: 0.65, 0.73) and a scaled integrated Brier score (IBS) of 0.13 (13% performance improvement over Kaplan-Meier estimates). For the post-treatment model, discriminative power was strong, with a mean AUC of 0.82 (95% CI: 0.79, 0.85) and a scaled IBS of 0.19. In the BART model, the most important feature was female age and embryo utilization rate (EUR) in the pre- and post-treatment models, respectively.</p><p><strong>Large scale data: </strong>N/A.</p><p><strong>Limitations reasons for caution: </strong>Our study is limited by the retrospective and ","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag085"},"PeriodicalIF":8.6,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13693365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Human reproduction openPub Date : 2026-09-22eCollection Date: 2026-01-01DOI: 10.1093/hropen/hoag084
Giuseppe Silvestri, Steve Rooks, Alejandro Chavez-Badiola, Silvana Perez, Stephanie Kuku, Alan Murray, David Sable, G David Adamson
{"title":"Cost-to-baby as a percentage of median household income predicts population-level access to ART: a global health economics analysis.","authors":"Giuseppe Silvestri, Steve Rooks, Alejandro Chavez-Badiola, Silvana Perez, Stephanie Kuku, Alan Murray, David Sable, G David Adamson","doi":"10.1093/hropen/hoag084","DOIUrl":"10.1093/hropen/hoag084","url":null,"abstract":"<p><strong>Study question: </strong>Does cost-to-baby, expressed as a percentage of median household income (HHI), predict population-level utilization of ART across countries?</p><p><strong>Summary answer: </strong>ART affordability follows a power-law relationship with population-level utilization (<i>R</i> <sup>2</sup> = 0.77-0.84), with highest-utilization countries consistently achieving gross cost-to-baby below 100% and net out-of-pocket cost-to-baby below 50% of median HHI.</p><p><strong>What is known already: </strong>Cost has been consistently identified as a dominant barrier to ART access worldwide, and earlier cross-national work has shown that per-cycle IVF cost as a proportion of disposable income is associated with national utilization. However, no prior analysis has used the cumulative cost of achieving a live birth, normalized it to median HHI, tested a non-linear functional form, or separated gross from net (out-of-pocket) cost as independent predictors.</p><p><strong>Study design size duration: </strong>Cross-national study using secondary aggregate data from ART registries and economic/demographic agencies for reporting years 2021-2023, covering 22 countries and regions that together represent more than 95% of estimated global ART cycle volume.</p><p><strong>Participants/materials setting methods: </strong>ART cycle volumes and live births were extracted from ICMART, ESHRE EIM, CDC NASS, CARTR, HFEA, REDLARA, ANZARD, and national registries. Median after-tax disposable HHI data were sourced from the Organisation for Economic Cooperation and Development (OECD) and World Bank, while female population aged 15-49 years and total live births were obtained from the United Nations Population Division. Gross cost-to-baby was calculated as the product of mean per-cycle cost (including embryo transfer, preimplantation genetic testing weighted by national usage, and medications) and the age-weighted number of cycles required to achieve a live birth. Net out-of-pocket cost-to-baby was derived after applying published reimbursement schedules, subsidies, and tax benefits, with structured estimates where authoritative published data were unavailable. Both metrics were expressed as a percentage of median HHI. Utilization was measured as the percentage of total national live births achieved via ART and as ART births per 1000 women aged 15-49 years. Power-law (log-log) regression was fitted by ordinary least squares; a subgroup analysis was performed for women aged 38-49 years. A Monte Carlo probabilistic sensitivity analysis (10 000 iterations; Program Evaluation and Review Technique (PERT) distributions with uncertainty bands of ±5%, ±7.5%, or ±10% calibrated to data-source quality) generated 90% simulation envelopes around each baseline regression.</p><p><strong>Main results and the role of chance: </strong>Gross cost-to-baby varied more than 12-fold across countries, ranging from 66% of median HHI in Israel to 833% in Africa (excluding Egypt","PeriodicalId":73264,"journal":{"name":"Human reproduction open","volume":"2026 4","pages":"hoag084"},"PeriodicalIF":8.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}